Summary
The TACKLE trial was a phase 3, randomised, double-blind, placebo-controlled trial examining the efficacy and safety of intramuscular tixagevimab–cilgavimab, a long-acting monoclonal antibody combination, for early outpatient treatment of COVID-19. Published in The Lancet Respiratory Medicine in 2022, the trial enrolled a large, geographically diverse population across multiple countries. As suggested by the study design and journal scope, the research aimed to establish whether this combination therapy could reduce disease severity or progression in non-hospitalised patients when administered early in infection.
UK applicability
Findings would be directly relevant to United Kingdom clinical practice and NHS outpatient COVID-19 management protocols, given the multi-national design and regulatory context of The Lancet Respiratory Medicine. However, applicability may depend on UK-specific epidemiology, variant prevalence, and integration with existing treatment guidelines at the time of publication.
Key measures
As suggested by the trial design: likely disease progression, severity, hospitalisation rates, and adverse events in early outpatient COVID-19 treatment
Outcomes reported
The study measured efficacy and safety of intramuscular tixagevimab–cilgavimab administration in non-hospitalised COVID-19 patients, as suggested by the phase 3 randomised controlled design and journal scope.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.